Companies that use eClinical Solutions

Source: Analysis of tech stacks from 58 companies that use eClinical Solutions

I noticed that companies using eClinical Solutions are clearly in the clinical research and life sciences space, specifically running clinical trials. The dominant presence of Medidata Rave and Veeva Vault, both specialized platforms for clinical trial data management and regulatory submissions, tells me these are pharmaceutical companies, biotech firms, or contract research organizations actively conducting drug development studies.

The pairing with Medidata Rave makes perfect sense because clinical trials require multiple integrated systems. eClinical Solutions likely handles specific aspects of trial management while Medidata Rave manages the electronic data capture and clinical data. Similarly, Veeva Vault appearing so frequently suggests these companies need robust document management for regulatory compliance and submission processes. Benchling's presence indicates many of these organizations also have upstream research and development activities, managing lab workflows and scientific data alongside their clinical operations. The OfficeSpace Software correlation is interesting because clinical trial sites often manage physical lab and office space across multiple locations, requiring space planning tools.

The full stack reveals these are enterprise-level organizations operating in a heavily regulated environment. They're dealing with complex, multi-year sales cycles typical of B2B healthcare and pharma. These companies are likely mid-to-late stage, with established clinical programs requiring enterprise-grade compliance and data management infrastructure. This isn't a product-led growth motion. These are relationship-driven sales with long implementation cycles.

Source: Analysis of Linkedin bios of 58 companies that use eClinical Solutions

I analyzed these 55 companies and found that eClinical Solutions primarily serves biotechnology and pharmaceutical companies developing novel therapies for serious diseases. These aren't software companies or general healthcare providers. They're drug developers, often focused on oncology, rare diseases, and genetic conditions. They're creating actual medicines, from targeted cancer treatments to gene therapies, and they need clinical trial infrastructure to prove their drugs work.

These companies span the full lifecycle, but lean heavily toward clinical and commercial stages. I see many post-IPO companies (Revolution Medicines, Kymera, Ultragenyx, BioMarin) alongside clinical-stage biotechs (Volastra, Akamis Bio) and even pharmaceutical giants (Takeda, Sanofi, Bristol Myers Squibb). Employee counts range from under 50 to over 30,000. The sweet spot appears to be companies with 200 to 2,000 employees who have molecules in human trials and need sophisticated clinical operations support.